| Year |
Citation |
Score |
| 2020 |
Pulido I, Ollosi S, Aparisi S, Becker JH, Aliena-Valero A, Benet M, Rodríguez ML, López A, Tamayo-Torres E, Chuliá-Peris L, García-Cañaveras JC, Soucheray M, Dalheim AV, Salom JB, Qiu W, ... ... Shimamura T, et al. Endothelin-1-mediated Drug Resistance in EGFR-mutant NSCLC. Cancer Research. PMID 32747363 DOI: 10.1158/0008-5472.Can-20-0141 |
0.301 |
|
| 2018 |
Pulido I, Becker J, Aupi M, Cañaveras JCG, Alcacer J, Rodríguez M, Martín P, Perales J, Aparisi S, Chulia L, Lafuente A, Alcoriza M, Mena S, Pereda J, Galbis-Carabajal J, ... ... Shimamura T, et al. Abstract LB-099: Metabolic vulnerabilities of mesenchymal-like EGFR-mutant NSCLC cells with acquired resistance to tyrosine kinase inhibitors Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-099 |
0.399 |
|
| 2018 |
Becker JH, Kahle MP, Soucheray M, Pulido I, Al-Shahrour F, Pino MSd, Wong K, Carretero J, Shimamura T. Abstract LB-085: A new role for LKB1 to regulate Heat Shock Protein 90 activity Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-085 |
0.432 |
|
| 2018 |
Ollosi SL, Soucheray M, Becker J, Pulido I, Dalheim A, Al-Shahrour F, Qui W, Nishimura M, Carretero J, Kaja S, Shimamura T. Abstract 20: Inhibition of mutant EGFR in NSCLC promotes endothelin-1-mediated NSCLC disease progression and angiogenesis Cancer Research. 78: 20-20. DOI: 10.1158/1538-7445.Am2018-20 |
0.449 |
|
| 2017 |
Rusan M, Li K, Li Y, Christensen CL, Abraham BJ, Kwiatkowski N, Buczkowski KA, Bockorny B, Chen T, Li S, Rhee K, Zhang H, Chen W, Terai H, Tavares T, ... ... Shimamura T, et al. Suppression of adaptive responses to targeted cancer therapy by transcriptional repression. Cancer Discovery. PMID 29054992 DOI: 10.1158/2159-8290.Cd-17-0461 |
0.362 |
|
| 2016 |
Shimamura T. Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Response. Cancer Research. 76: 3111. PMID 27197235 DOI: 10.1158/0008-5472.Can-16-0610 |
0.38 |
|
| 2016 |
Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra Cuentas ER, Wistuba II, Soucheray M, ... ... Shimamura T, et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment. Cancer Research. PMID 26833127 DOI: 10.1158/0008-5472.Can-15-1439 |
0.379 |
|
| 2016 |
Repellin CE, Eser PO, Capelletti M, Shimamura T, Ercan D, Xu C, Gray NS, Wong K, Jänne PA. Abstract 890: TGFâ upregulation mediates growth retardation in EGFR T790M mutant non-small cell lung cancer Cancer Research. 76: 890-890. DOI: 10.1158/1538-7445.Am2016-890 |
0.478 |
|
| 2015 |
Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker JH, Kikuchi E, Xu C, Patel TB, Al-Shahrour F, Carretero J, Wong KK, Jänne PA, Shapiro GI, Shimamura T. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Research. PMID 26282169 DOI: 10.1158/0008-5472.Can-15-0377 |
0.426 |
|
| 2015 |
Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker JH, Kikuchi E, Xu C, Patel TB, Al-shahrour F, Carretero J, Wong K, Janne PA, Shapiro GI, Shimamura T. Abstract 766: Suppression of gefitinib-induced EMT in EGFR mutant NSCLC preferentially selects for acquired T790M Cancer Research. 75: 766-766. DOI: 10.1158/1538-7445.Am2015-766 |
0.414 |
|
| 2015 |
Pulido I, Pascual JL, Soucheray M, Rodriguez ML, Crespo DT, Aparisi S, Sirerol JA, Mena S, Pereda J, Al-shahrour F, Ortega AL, Shimamura T, Carretero J. Abstract 753: Genomic alterations of autophagy genes disrupts autophagic flux in human lung adenocarcinomas Cancer Research. 75: 753-753. DOI: 10.1158/1538-7445.Am2015-753 |
0.436 |
|
| 2015 |
Akbay EA, Koyama S, Li Y, Herter-Sprie GS, Thai TC, Aref AR, Soucheray M, Shimamura T, Barbie DA, Dranoff G, Hammerman PS, Wong K. Abstract 1355: Functional inactivation of LKB1 increases the production of pro-inflammatory cytokines and governs response to immune modulation Cancer Research. 75: 1355-1355. DOI: 10.1158/1538-7445.Am2015-1355 |
0.389 |
|
| 2015 |
Becker JH, Gao Y, Pulido I, Kikuchi E, Soucheray M, Gandhi R, Christensen CL, Al-shahrour F, Wong K, Carretero J, Shimamura T. Abstract LB-C21: CXCR7 expression is necessary for the maintenance of mesenchymal phenotype in acquired EGFR TKI resistance in NSCLC Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-C21 |
0.441 |
|
| 2015 |
Kahle M, Soucheray M, Becker J, Kikuchi E, Pulido I, Akbay E, Christensen C, Qiu W, Al-Shahrour F, Johnson N, Carretero J, Wong K, Shimamura T. Abstract C75: Overcoming KRAS/LKB1 mutant NSCLC resistance to BET bromodomain inhibitors with gemcitabine or Mcl-1 inhibition Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C75 |
0.417 |
|
| 2015 |
Piñeiro-Yáñez E, Reboiro-Jato M, Perales-Patón J, Glez-Peña D, Tejero H, Shimamura T, Carretero J, Valencia A, Hidalgo M, Al-Shahrour F. Abstract A22: PanDrugsDB: Identifying druggable genetic dependencies for personalized cancer therapy Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A22 |
0.314 |
|
| 2015 |
Christensen C, Kwiatkowski N, Abraham B, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie G, Akbay E, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel J, Cavanaugh J, et al. Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor Cancer Cell. 27: 149. DOI: 10.1016/J.Ccell.2014.12.007 |
0.372 |
|
| 2014 |
Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 26: 909-22. PMID 25490451 DOI: 10.1016/J.Ccell.2014.10.019 |
0.391 |
|
| 2013 |
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, ... ... Shimamura T, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discovery. 3: 1355-63. PMID 24078774 DOI: 10.1158/2159-8290.Cd-13-0310 |
0.387 |
|
| 2013 |
Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6183-92. PMID 24045185 DOI: 10.1158/1078-0432.Ccr-12-3904 |
0.429 |
|
| 2013 |
Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O'Brien ET, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY. HIF1α and HIF2α independently activate SRC to promote melanoma metastases. The Journal of Clinical Investigation. 123: 2078-93. PMID 23563312 DOI: 10.1172/Jci66715 |
0.369 |
|
| 2013 |
Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, Gray NS, Jänne PA. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Research. 73: 834-43. PMID 23172312 DOI: 10.1158/0008-5472.Can-12-2066 |
0.384 |
|
| 2013 |
Christensen CL, Shimamura T, Akbay EA, Michaelsen SR, Poulsen HS, Wong K. Abstract 3126: Insulinoma-associated 1 is a key transcriptional regulator of growth and survival-promoting pathways in small cell lung cancer. Cancer Research. 73: 3126-3126. DOI: 10.1158/1538-7445.Am2013-3126 |
0.423 |
|
| 2013 |
Rodriguez ML, Pulido I, Soucheray M, Crespo D, Al-shahrour F, Shimamura T, Ortega A, Carretero J. Abstract 1690: Differential autophagy activation in KRAS and EGFR mutant lung adenocarcinomas. Cancer Research. 73: 1690-1690. DOI: 10.1158/1538-7445.Am2013-1690 |
0.454 |
|
| 2013 |
Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay EA, Kimmelman AC, Kung AL, Bradner JE, Wong KK. Abstract 1126: Efficacy of BET bromodomain inhibition in Kras-positive non-small cell lung cancer. Cancer Research. 73: 1126-1126. DOI: 10.1158/1538-7445.Am2013-1126 |
0.45 |
|
| 2013 |
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha J, Christensen C, Shimamura T, Sholl L, Rodig S, Freeman G, Hammerman P, Dranoff G, Wong K. Abstract B290: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B290 |
0.415 |
|
| 2013 |
Crespo D, Pulido I, Rodriguez ML, Aparisi S, Lopez A, Soucheray M, Al-Shahrour F, Shimamura T, Ortega A, Carretero J. Abstract A292: Salinomycin, an anti-cancer stem cell antibiotic, overcomes acquired resistance to BRAF inhibitors in BRAF-mutant human melanoma cell lines. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A292 |
0.426 |
|
| 2012 |
Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discovery. 2: 934-47. PMID 22961667 DOI: 10.1158/2159-8290.Cd-12-0103 |
0.399 |
|
| 2012 |
Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4973-85. PMID 22806877 DOI: 10.1158/1078-0432.Ccr-11-2967 |
0.357 |
|
| 2012 |
Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell. 21: 751-64. PMID 22698401 DOI: 10.1016/J.Ccr.2012.03.048 |
0.346 |
|
| 2012 |
Straume O, Shimamura T, Lampa MJ, Carretero J, Øyan AM, Jia D, Borgman CL, Soucheray M, Downing SR, Short SM, Kang SY, Wang S, Chen L, Collett K, Bachmann I, et al. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 8699-704. PMID 22589302 DOI: 10.1073/Pnas.1017909109 |
0.365 |
|
| 2012 |
Xu L, Kikuchi E, Xu C, Ebi H, Ercan D, Cheng KA, Padera R, Engelman JA, Jänne PA, Shapiro GI, Shimamura T, Wong KK. Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Research. 72: 3302-11. PMID 22552292 DOI: 10.1158/0008-5472.Can-11-3720 |
0.442 |
|
| 2012 |
Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 483: 613-7. PMID 22425996 DOI: 10.1038/Nature10937 |
0.336 |
|
| 2011 |
Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Research. 71: 6051-60. PMID 21791641 DOI: 10.1158/0008-5472.Can-11-1340 |
0.438 |
|
| 2011 |
Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S, Kufe D. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Molecular Cancer Therapeutics. 10: 806-16. PMID 21421804 DOI: 10.1158/1535-7163.Mct-10-1050 |
0.411 |
|
| 2011 |
Shimamura T, Carretero J, Xu C, Capelletti M, Rikova K, Gu T, Kobayashi S, Rogers A, Janne PA, Wong K, Shapiro GI. Abstract LB-399: Chronic inhibition of mutant EGFR in NSCLC leads to EGFR TKI resistance by TGF-β1 mediated epithelial to mesenchymal transition Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-399 |
0.416 |
|
| 2010 |
Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, Xu C, Wang Y, Adelmant GO, Capelletti M, Lee HJ, Rodig SJ, Borgman C, Park SI, Kim HR, et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Research. 70: 9827-36. PMID 20952506 DOI: 10.1158/0008-5472.Can-10-1671 |
0.427 |
|
| 2010 |
Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, Walton ZE, Gu TL, Silva JC, Crosby K, Shapiro GI, et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell. 17: 547-59. PMID 20541700 DOI: 10.1016/J.Ccr.2010.04.026 |
0.362 |
|
| 2010 |
Will B, Siddiqi T, Jordà MA, Shimamura T, Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG, Kobayashi S. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 115: 2901-9. PMID 20160166 DOI: 10.1182/Blood-2009-03-209544 |
0.358 |
|
| 2010 |
Liang MC, Ma J, Chen L, Kozlowski P, Qin W, Li D, Goto J, Shimamura T, Hayes DN, Meyerson M, Kwiatkowski DJ, Wong KK. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene. 29: 1588-97. PMID 19966866 DOI: 10.1038/Onc.2009.452 |
0.39 |
|
| 2010 |
Shimamura T, Fujisawa T, Husain SR, Joshi B, Watanabe S, Kato S, Fujita K, Takahashi H, Yoneda M, Gotou A, Kobayashi N, Kubota K, Ichikawa Y, Nakajima A, Puri RK. M1962 Overexpression of Interleukin-13 Receptor-Alpha2 in Pancreatic Ductal Adenocarcinoma: A Novel Target for Receptor Directed Anti-Cancer Therapy Gastroenterology. 138: S-448. DOI: 10.1016/S0016-5085(10)62072-0 |
0.311 |
|
| 2009 |
Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M, Li D, Ullrich R, Koker M, Fischer F, Shimamura T, Rauh D, Mermel C, Fischer S, Stückrath I, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. The Journal of Clinical Investigation. 119: 1727-40. PMID 19451690 DOI: 10.1172/Jci37127 |
0.392 |
|
| 2009 |
Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, Shimamura T, Miller DS, Sharpless NE, Bardeesy N, Kwiatkowski DJ, Schorge JO, Wong KK, Castrillon DH. Somatic LKB1 mutations promote cervical cancer progression. Plos One. 4: e5137. PMID 19340305 DOI: 10.1371/Journal.Pone.0005137 |
0.347 |
|
| 2009 |
Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proceedings of the National Academy of Sciences of the United States of America. 106: 474-9. PMID 19122144 DOI: 10.1073/Pnas.0808930106 |
0.434 |
|
| 2009 |
Foley KP, Shimamura T, Blackman RK, Borgman CL, Inoue T, Korbut T, Proia D, Sang J, Ogawa LS, Smith D, Tatsuta N, Zhang C, Zhang H, Ying W, Shapiro GI, et al. Abstract C91: Pharmacodynamic analysis of the Hsp90 inhibitor STA‐9090 in a lung cancer xenograft model supports an infrequent dosing schedule in the clinic Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C91 |
0.411 |
|
| 2009 |
Carretero J, Shimamura T, Rikova K, Gu T, Borgman CL, Buttarazzi S, McNamara KL, Brandstetter KA, Silva JC, Shapiro GI, Castrillon DH, Maira M, García‐Echeverría C, Kim CF, Bardeesy N, et al. Abstract B103: Integrative genomic and proteomic analyses identify novel targets for Lkb1 deficient metastatic lung tumors Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B103 |
0.416 |
|
| 2008 |
Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, Borgman CL, Tawadros S, Li H, Sos ML, Backes H, Shapiro GI, Wolf J, Jacobs AH, Thomas RK, et al. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). Plos One. 3: e3908. PMID 19079597 DOI: 10.1371/Journal.Pone.0003908 |
0.418 |
|
| 2008 |
Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA, Zaghlul S, Thomas RK, Greulich H, Kobayashi S, Chirieac LR, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Research. 68: 5827-38. PMID 18632637 DOI: 10.1158/0008-5472.Can-07-5428 |
0.45 |
|
| 2008 |
Shimamura T, Shapiro GI. Heat shock protein 90 inhibition in lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: S152-9. PMID 18520302 DOI: 10.1097/Jto.0B013E318174Ea3A |
0.422 |
|
| 2008 |
Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 27: 4702-11. PMID 18408761 DOI: 10.1038/Onc.2008.109 |
0.465 |
|
| 2008 |
Smith D, Shimamura T, Barbera S, Bejcek BE. NF-kappaB controls growth of glioblastomas/astrocytomas. Molecular and Cellular Biochemistry. 307: 141-7. PMID 17828582 DOI: 10.1007/S11010-007-9593-4 |
0.718 |
|
| 2007 |
Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Research. 67: 11924-32. PMID 18089823 DOI: 10.1158/0008-5472.Can-07-1885 |
0.426 |
|
| 2007 |
Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, Letai A. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Research. 67: 11867-75. PMID 18089817 DOI: 10.1158/0008-5472.Can-07-1961 |
0.432 |
|
| 2007 |
Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 448: 807-10. PMID 17676035 DOI: 10.1038/Nature06030 |
0.386 |
|
| 2007 |
Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell. 12: 81-93. PMID 17613438 DOI: 10.1016/J.Ccr.2007.06.005 |
0.439 |
|
| 2007 |
Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS, Shimamura T, Shapiro G, Lee JC, Ji H, Feng W, Chen TH, Yanagisawa H, Wong KK, Meyerson M. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biology & Therapy. 6: 661-7. PMID 17495523 DOI: 10.4161/Cbt.6.5.4003 |
0.428 |
|
| 2007 |
Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt KA, Liniker E, Borgman CL, Haringsma HJ, Feng W, Weir BA, Lowell AM, Lee JC, Wolf J, Shapiro GI, Wong KK, et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 26: 5023-7. PMID 17311002 DOI: 10.1038/Sj.Onc.1210292 |
0.476 |
|
| 2007 |
Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Scott AM, Jungbluth AA, Cavenee WK, Old LJ, Demetri GD, et al. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. The Journal of Clinical Investigation. 117: 346-52. PMID 17256054 DOI: 10.1172/Jci30446 |
0.437 |
|
| 2007 |
Shimamura T, Greulich H, Solca FF, Wong K. C7-04: Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model Journal of Thoracic Oncology. 2: S380. DOI: 10.1097/01.Jto.0000283232.53465.68 |
0.374 |
|
| 2006 |
Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Research. 66: 11389-98. PMID 17145885 DOI: 10.1158/0008-5472.Can-06-2318 |
0.457 |
|
| 2006 |
Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI, Wong KK. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Research. 66: 6487-91. PMID 16818618 DOI: 10.1158/0008-5472.Can-06-0971 |
0.456 |
|
| 2006 |
Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 9: 485-95. PMID 16730237 DOI: 10.1016/J.Ccr.2006.04.022 |
0.448 |
|
| 2006 |
Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 103: 7817-22. PMID 16672372 DOI: 10.1073/Pnas.0510284103 |
0.46 |
|
| 2005 |
Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Research. 65: 6401-8. PMID 16024644 DOI: 10.1158/0008-5472.Can-05-0933 |
0.435 |
|
| 2002 |
Shimamura T, Hsu TC, Colburn NH, Bejcek BE. Activation of NF-kappaB is required for PDGF-B chain to transform NIH3T3 cells. Experimental Cell Research. 274: 157-67. PMID 11855867 DOI: 10.1006/Excr.2001.5449 |
0.716 |
|
| 2001 |
Murphy K, Shimamura T, Bejcek BE. Use of fluorescently labeled DNA and a scanner for electrophoretic mobility shift assays. Biotechniques. 30: 504-6, 508. PMID 11252786 DOI: 10.2144/01303Bm07 |
0.655 |
|
| 2000 |
Jazayeri A, McGee J, Shimamura T, Cross SB, Bejcek BE. SHP-2 can suppress transformation induced by platelet-derived growth factor. Experimental Cell Research. 254: 197-203. PMID 10640417 DOI: 10.1006/Excr.1999.4741 |
0.691 |
|
| Show low-probability matches. |